IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Unraveling Diabetic Neuropathy: Pathophysiology, Diagnosis, and Emerging Therapies

Sonika Kashyap, Vandana Jhalora, Renu Bist*

Author's Affiliation

Department of Zoology, University of Rajasthan, Jaipur-302004, Rajasthan, India

Abstract: Diabetic neuropathy, a common complication of diabetes, causes significant nerve damage and a variety of symptoms like pain, numbness, and weakness. This review delves into how high blood sugar levels contribute to the condition through oxidative stress and metabolic issues. It covers the range of symptoms and the methods used to diagnose the disease, emphasizing the importance of thorough clinical assessments. Current treatments focus on controlling blood sugar and managing symptoms, but new therapies offer hope for better outcomes. Future research aims to overcome existing challenges and improve prevention, diagnosis, and treatment, ultimately enhancing the quality of life for those affected.

Index Terms - Diabetic Neuropathy, hyperglycemia, oxidative stress, diabetic mellitus, reactive oxygen species

I. INTRODUCTION

Diabetic neuropathy is a debilitating complication of diabetes, characterized by nerve damage primarily due to prolonged hyperglycemia. Affecting nearly half of all diabetes patients, this condition significantly impairs quality of life by causing pain, sensory loss, and motor dysfunction. The pathophysiology of diabetic neuropathy is complex and multifactorial, involving oxidative stress, inflammation, vascular insufficiency, and metabolic disturbances. Hyperglycemia leads to the accumulation of advanced glycation end-products (AGEs), which exacerbate oxidative stress and inflammatory pathways, ultimately damaging nerve cells (Pop-Busui et al., 2022).

Clinically, diabetic neuropathy manifests in various forms, including peripheral, autonomic, and focal neuropathies, each presenting unique challenges in diagnosis and management (Fig 1). Peripheral neuropathy, the most common form, typically starts in the extremities, causing symptoms like numbness, tingling, and sharp pains (Fig 2). Autonomic neuropathy affects internal organs, leading to gastrointestinal, cardiovascular, and genitourinary dysfunctions (Bodman et al., 2024).

Diagnosis relies on a combination of clinical examination, patient history, and specialized tests such as nerve conduction studies and quantitative sensory testing. Early detection and intervention are crucial to prevent progression and manage symptoms effectively. Current treatment strategies focus on glycemic control, pain management, and addressing specific neurological deficits. However, emerging therapies, including neuroprotective agents, regenerative medicine, and gene therapy, hold promise for more effective management and potential reversal of nerve damage (Carmichael et al., 2021). This review explores the intricate pathophysiology, clinical manifestations, diagnostic approaches, and cutting-edge therapies for diabetic neuropathy.



Figure 1: Different forms of Diabetic Neuropathy

1. PATHOPHYSIOLOGY OF DIABETIC NEUROPATHY

Diabetic neuropathy is a unique neurodegenerative dis order of the peripheral nervous system that preferentially targets sensory axons, autonomic axons and later, to a lesser extent, motor axons (Feldman et al., 2019). The exact mechanisms behind diabetic peripheral neuropathy (DPN) are not yet fully understood. However, it is believed to stem primarily from a range of physiological changes triggered by high blood sugar, lipid metabolism issues, and disrupted insulin signaling pathways. These include the polyol, glycolytic, hexosamine, protein kinase C (PKC), advanced glycation end products (AGEs), and poly(ADP-ribose) polymerase pathway pathways (Fig 3). These pathways, either independently or in combination, can lead to endoplasmic reticulum stress, mitochondrial dysfunction, DNA damage, and increased inflammatory signaling (Zang et al., 2023).

Figure 2: Symptoms of Diabetic Neuropathy

1.1 Polyol Pathway

The polyol pathway is a key process believed to contribute to diabetic neuropathy. In this pathway, excess glucose is converted into sorbitol by the enzyme aldose reductase (Feldman et al., 2017). This conversion causes an osmotic imbalance in cells due to the buildup of sorbitol, leading to osmotic stress and a compensatory outflow of inositol and taurine. The loss of inositol results in damage to the normal functional structure of nerve cells. Excessive activation of the polyol pathway promotes the occurrence of neuropathy. Increased production of reactive oxygen species leads to oxidative stress. Sorbitol is then converted to fructose by sorbitol dehydrogenase (Niimi et al., 2021; Papachristoforou et al., 2020).

In pre-clinical studies using the streptozotocin (STZ) rat model of Type 1 Diabetes (T1D), researchers have observed that the polyol pathway gets activated, leading to a series of harmful effects. This activation results in damage to the peripheral nervous system (PNS), affecting both its structure and function. The studies show how the build-up of sorbitol and the reduction in important molecules like NADPH can contribute to nerve damage, highlighting the pathway's role in the complications associated with diabetes (Cameron & Cotter, 1993).

1.2 Advanced glycation end pathway

When proteins and lipids come into contact with high blood sugar levels, they create a variety of highly reactive molecules known as glycation end products. Some examples include glycohemoglobin, carboxymethyl arginine, and pentosidine (Vargas-Soria et al., 2023). These glycation end products interact with specific receptors on cells, which can set off a chain reaction. This reaction activates signals and markers that drive inflammation, such as NF-kB, TNF-α, and interleukin. This process then leads to further inflammation in the body causing glial cell dysfunction and microvascular damage (Parwani & Mandal, 2023).

Extracellular protein AGEs, which are found in the plasma and matrix, can interfere with how cells stick together and trigger the receptor known as RAGE (Ramasamy et al., 2007). When AGEs bind to RAGE, it activates a protein called nuclear factor kappa B (NF-κB). NF-κB plays a role in various cellular processes, including inflammation and cell death. In nerve cells, activating RAGE can lead to increased oxidative stress by stimulating NADPH oxidase, which contributes to further cellular damage (Vincent et al., 2007).

1.3 Protein kinase C pathway

The Protein Kinase C (PKC) pathway is a key player in how high blood sugar levels lead to damage in tissues that are prone to diabetes-related complications. When blood glucose levels are elevated, it triggers the production of diacylglycerol (DAG), which activates PKC. This pathway is particularly important in diabetic neuropathy and other complications (Arikawa et al., 2007).

When PKC gets activated, it triggers the activation and phosphorylation of ATPase. This process can lead to several problems, including metabolic damage and disruptions in the body's normal functions. Specifically, it can alter factors that control blood vessel growth, causing blood vessels to constrict, and impact the body's overall metabolism (Huang et al., 2022).

1.4 Hexosamine pathway

The hexosamine pathway is another way that high blood sugar can lead to diabetic peripheral neuropathy (DPN). When blood sugar levels are too high, this pathway gets activated, causing damage to both Chevon cells and nerve cells through oxidative stress and inflammation.

Under normal conditions, only a small amount of fructose-6-phosphate, a product of glycolysis, enters this pathway. It gets converted into glucosamine-6-phosphate by an enzyme called glutamine fructose-6-phosphate amidotransferase. However, when blood sugar levels are high, this process becomes more active, contributing to nerve damage and DPN (Thornalley, 2005). Glucosamine-6 phosphate is then transformed into uridine diphosphate-N-acetyl glucosamine (UDP-GlcNAc). This molecule plays a crucial role by attaching to specific parts of transcription factors—namely, the serine and threonine residues. This attachment can influence how these transcription factors function, impacting various cellular processes (Brownlee, 2001).

1.5 Poly(ADP-ribose) polymerase pathway

Poly(ADP-ribose) polymerase (PARP) is an enzyme found in the nucleus that's crucial for repairing DNA and has several other important functions. It's often used as a marker for diabetic peripheral neuropathy (DPN) (Adki & Kulkarni, 2023). Among its types, PARP-1 is the most prevalent and plays a key role in fixing DNA and preserving the genome's integrity. Beyond this, PARP-1 also influences how the body responds to inflammation, cell death, and other critical processes by regulating the expression of various proteins at the transcriptional level (Pacher & Szabó, 2005).



Figure 3: Pathophysiological pathways involved in Diabetic Neuropathy

1.6 Oxidative Stress

When blood sugar levels are too high and blood flow is reduced, it overwhelms the mitochondria, the tiny powerhouses inside our cells. This overload leads to a buildup of harmful chemicals leading to oxidative stress, which can damage the mitochondria. As a result, nerve cells start to deteriorate and eventually die.

Under normal circumstances, mitochondria generate reactive oxygen species (ROS) and reactive nitrogen species (RNS) as part of their energy production process. ROS like superoxide and hydrogen peroxide are usually kept in check by the cell's natural defenses, such as superoxide dismutase, catalase, and glutathione (Leinninger et al., 2006). But when blood sugar is high, mitochondria work harder and produce more ROS. One of the RNS, peroxynitrite, is created when superoxide reacts with nitric oxide (NO). This compound can cause various problems in the cell, such as damaging proteins and activating PARP, an enzyme involved in DNA repair. As ROS and RNS levels rise, they start to overwhelm the cell's ability to defend itself. This leads to damage in cell membranes, proteins, and DNA, ultimately disrupting the cell's function and integrity. Since mitochondria are the main source of ROS and RNS, they are especially vulnerable to damage (Obrosova et al., 2002).

2. DIAGNOSTIC APPROACHES

For most people, diagnosing diabetic neuropathy is mainly based on their symptoms and a physical exam. The condition often starts with feelings of numbness, tingling, pain, and weakness, usually beginning in the toes and moving up towards the knees. As it progresses, the symptoms can spread to the fingers and other parts of the upper limbs.

When doctors examine someone for diabetic neuropathy, they look for specific changes in sensation. They typically check how well the person can feel different types of stimuli, such as pinpricks, temperature changes (especially cold), vibrations, and joint movements. The pattern of sensation loss often resembles wearing a "stocking and glove" – meaning the loss starts at the extremities (like the toes and fingers) and moves inward (Divisova et al., 2012).

To test these sensations, doctors might first apply a stimulus to an area where the response should be normal, such as the forehead. They then move the stimulus to the toe and gradually up the leg, noting where the sensation starts to return to normal. Pinprick sensation is tested with a sharp object, like a safety pin, which is used once per patient and then discarded. Temperature is checked with a cool metal object. Vibration is assessed using a vibrating tuning fork placed on the bony part of the big toe, and proprioception (sense of joint position) is examined by moving the toe's joint slightly (Tesfaye et al., 2010).

3. CURRENT TREATMENT STRATEGIES

The consistent feature between Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) is hyperglycemia; therefore, treatment of hyperglycemia logically would be the best preventive treatment for diabetic neuropathy. Recent findings have shown that keeping blood sugar levels well-controlled can have a significant impact on preventing neuropathy in people with T1DM. However, the same level of control doesn't seem to have as strong an effect for those with T2DM.

3.1 Preventive Strategies for Diabetic Neuropathy

Preventing diabetic neuropathy and its complications remains the most effective strategy. Maintaining optimal blood sugar levels reduces the risk of developing severe peripheral neuropathy, although it increases the risk of hypoglycemia. Patients with diabetes should also receive guidance on proper foot care and footwear to protect insensitive areas and pressure points, which helps prevent painless ulcers and reduces the risk of bone infections. Specialized foot clinics are best equipped to handle the prevention and treatment of diabetic foot issues. While pancreas transplantation has shown potential in stabilizing neuropathy, it is not yet a routine procedure (Giurini et al., 1998; Martin et al., 2006).

3.2 Pharmacological Management of Focal Neuropathies

For focal neuropathies, such as cranial nerve palsy, painful diabetic neuropathy (PDN), and truncal neuropathy, the condition often resolves on its own within a few months. However, managing pain can be challenging, especially in conditions like large fiber diabetic peripheral neuropathy (LDDP) and focal neuropathies. Medications like carbamazepine, phenytoin, clonazepam, and paracetamol combined with

codeine phosphate can provide relief. Tricyclic antidepressants, such as imipramine or amitriptyline, are also effective, typically in doses ranging from 30–150 mg per day, but they may worsen postural hypotension. Newer medications like duloxetine and pregabalin have also proven useful. Treatment for postural hypotension is only necessary if symptoms are present, with midodrine (where available) being preferred before using 9-α-fluorohydrocortisone, which is effective but can cause hypertension.

3.3 Treatment of Multifocal Diabetic Neuropathies

Painful diabetic neuropathy (PDN) can be extremely painful and often resists conventional treatments. In such cases, a short-term course of corticosteroids might be considered, alongside adjustments in blood sugar control. It is important to remember that the overall prognosis for focal diabetic neuropathies is generally positive, with spontaneous improvement (Said et al., 1997, 2003).

4. EMERGING THERAPIES AND FUTURE DIRECTIONS

Diabetic neuropathy affects a significant portion of the diabetic population, contributing to considerable morbidity and reduced quality of life. Conventional treatment strategies include strict glycemic control and symptomatic management, yet these approaches often fall short in addressing the underlying nerve damage and preventing progression. This review aims to highlight recent advancements and potential future directions in the treatment of diabetic neuropathy, emphasizing the importance of innovative therapies that target the disease's multifactorial nature.

4.1 Novel Pharmacological Agents

4.1.1 Aldose Reductase Inhibitors (ARI): ARIs inhibit aldose reductase, the enzyme that converts glucose to sorbitol in the polyol pathway. By blocking this conversion, ARIs reduce sorbitol accumulation, mitigating osmotic and oxidative stress on nerve cells (Chalk et al., 2007). ARIs help decrease oxidative stress, which is a significant factor in nerve damage in diabetic neuropathy. Lower oxidative stress leads to reduced cellular damage and inflammation in nerves. Examples: Epalrestat, zenarestat, ranirestat.

4.1.2 Nerve Growth Factor (NGF) Therapy: NGF supports the survival and function of sensory and sympathetic neurons, which are often damaged in diabetic neuropathy (Aloe et al., 2015). NGF stimulates the growth and repair of nerve fibers, potentially reversing damage caused by diabetes. They also modulate inflammatory responses, reducing the inflammation that contributes to nerve damage in diabetic neuropathy.

4.1.3 Antioxidants: Since oxidative stress is a key component in the pathogenesis of diabetic neuropathy, antioxidants like alpha-lipoic acid and acetyl-L-carnitine are being studied for their neuroprotective effects (Oyenihi et al., 2015). Studies indicate that these antioxidants can reduce pain and improve sensory function in patients with diabetic neuropathy. It also enhances nerve fiber regeneration and may improve overall nerve function.

4.1.4 Anti-inflammatory Agents: Chronic inflammation contributes to nerve damage in diabetes. Agents targeting inflammatory pathways, such as cytokine inhibitors, are being explored for their potential benefits (Akbar et al., 2023). Cytokine inhibitors target specific pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) that contribute to nerve inflammation and damage in diabetic neuropathy. By reducing cytokine levels, these inhibitors can protect nerve cells from inflammatory damage, improving nerve function and alleviating symptoms.

4.2 Regenerative Medicine and Stem Cell Therapy

4.2.1 Stem Cell Therapy: Mesenchymal stem cells (MSCs) and neural stem cells (NSCs) have shown promise in preclinical studies for their ability to differentiate into neural cells and promote nerve regeneration (Akter et al., 2023).

4.2.2 Exosome Therapy: Exosomes derived from stem cells contain bioactive molecules that can promote tissue repair and regeneration (L. Wang et al., 2020). Exosomes are small vesicles that facilitate cell-to-cell communication, carrying proteins, lipids, and nucleic acids. They offer several therapeutic benefits, including anti-inflammatory effects, nerve regeneration, and immune response modulation. The advantages of exosome therapy include its minimally invasive nature, low immunogenicity, and targeted delivery capabilities.

4.3 Gene Therapy and Targeted Treatments

4.3.1 Gene Therapy: It involves introducing or altering genetic material within a patient's cells to treat or prevent the condition. This approach aims to correct or modify genes associated with nerve damage and inflammation, improve cellular function, and promote nerve repair. Techniques such as CRISPR/Cas9 are being explored to correct genetic defects associated with neuropathy. Gene delivery methods are being developed to enhance the expression of neuroprotective genes or inhibit the expression of harmful genes (Kessler et al., 2015).

4.3.2 Targeted Nanoparticle Delivery: Nanoparticles can be engineered to deliver therapeutic agents directly to affected nerves, increasing the efficacy and reducing systemic side effects (Bhandari et al., 2022) .

4.4 Advances in Pain Management

4.4.1 Transcranial Magnetic Stimulation (TMS): TMS is a non-invasive technique that uses magnetic fields to stimulate nerve cells in the brain. Studies are evaluating its efficacy in reducing neuropathic pain in diabetic patients (Onesti et al., 2013).

4.4.2 Peripheral Nerve Stimulation (PNS): PNS involves the use of electrical impulses to stimulate peripheral nerves and alleviate pain (E. J. Wang et al., 2022). Emerging technologies aim to improve the precision and effectiveness of PNS devices.

6.4.3 Virtual Reality (VR) Therapy: VR is being investigated as a pain management tool, providing immersive environments that can distract patients from pain and potentially alter pain perception (Alonso-Enríquez et al., 2023).

4.5 Biomarkers for Early Detection and Monitoring

4.5.1 Molecular Biomarkers: Identifying biomarkers such as specific proteins, lipids, or RNAs that correlate with the onset and progression of neuropathy can enable early diagnosis and monitoring of disease progression (Rossor & Reilly, 2022).

4.5.2 Imaging Techniques: Advanced imaging modalities, such as magnetic resonance neurography (MRN) and optical coherence tomography (OCT), are being refined to provide detailed visualization of nerve damage and monitor therapeutic responses (Fasoula et al., 2023).

4.6 Innovative Approaches and Technologies

4.6.1 Wearable Technology: Devices that monitor blood glucose levels, nerve function, and other physiological parameters in real-time can help manage diabetes and detect early signs of neuropathy (Brognara et al., 2021).

4.6.2 Artificial Intelligence (AI) and Machine Learning: AI algorithms are being developed to analyze large datasets from electronic health records, genetic information, and imaging studies to predict the risk of developing neuropathy and tailor personalized treatment plans (Khalifa & Albadawy, 2024).

4.6.3 Telemedicine: Telehealth platforms are enhancing access to care for patients with diabetic neuropathy, enabling remote monitoring and management by healthcare providers (Dhediya et al., 2023).

4.7 Future Directions

4.7.1 Personalized Medicine: Advances in genomics and biomarker discovery are paving the way for personalized treatment strategies tailored to the genetic and molecular profile of individual patients (Yaghmour et al., n.d.).

4.7.2 Combination Therapies: Combining multiple therapeutic approaches, such as pharmacological agents with stem cell therapy or gene therapy, may enhance treatment efficacy and address various aspects of the disease (Zheng et al., 2015).

5. RESEARCH CHALLENGES AND OPPORTUNITIES

5.1 Pathophysiological Understanding

5.1.1 Challenges

- Complex Mechanisms: The pathophysiology of diabetic neuropathy involves multiple mechanisms, including hyperglycemia-induced metabolic and vascular changes, oxidative stress, and inflammation (Bodman et al., 2024). The interplay between these factors complicates the understanding of the disease.
- Heterogeneity: Diabetic neuropathy is heterogeneous, with varying clinical manifestations and progression rates among patients. This heterogeneity makes it challenging to identify universal biomarkers and treatment targets.

5.1.2 Opportunities

- Advanced Research Techniques: Utilizing omics technologies (genomics, proteomics, metabolomics) can provide deeper insights into the molecular mechanisms underlying diabetic neuropathy (Darmayanti et al., 2021).
- Animal Models: Developing more accurate animal models that mimic the human condition can help in understanding disease mechanisms and testing new therapies.

5.2 Diagnostic Tools

5.2.1 Challenges

- Early Detection: Current diagnostic methods often detect neuropathy at advanced stages. There is a need for reliable biomarkers and non-invasive techniques for early detection.
- Standardization: Lack of standardized diagnostic criteria and methods leads to variability in diagnosis and assessment of disease severity.

5.2.2 Opportunities

- Biomarker Discovery: Research into molecular biomarkers (e.g., NF-L, microRNAs) holds promise for early detection and monitoring of disease progression (Fan et al., 2020).
- Imaging Technologies: Advances in imaging techniques, such as magnetic resonance neurography (MRN) and optical coherence tomography (OCT), offer potential for non-invasive and early diagnosis (Kollmer & Bendszus, 2021; Ong et al., 2022).

5.3 Treatment Strategies

5.3.1 Challenges

- Limited Efficacy of Current Therapies: Many current treatments only provide symptomatic relief rather than addressing the underlying disease processes.
- Side Effects: Pharmacological treatments often come with significant side effects, limiting their long-term use.

5.3.2 Opportunities

- Regenerative Medicine: Stem cell therapy and exosome therapy represent exciting opportunities for nerve regeneration and repair.

- Gene Therapy: Emerging gene editing technologies, such as CRISPR/Cas9, offer potential for correcting genetic defects and modulating disease-related pathways.

5.4 Emerging Technologies

5.4.1 Challenges

- Translation to Clinical Practice: Translating findings from preclinical studies to clinical practice remains a significant hurdle due to differences in disease manifestation and response to treatments.
- Regulatory and Ethical Issues: The use of novel therapies, such as gene editing and stem cell therapy, raises regulatory and ethical concerns that need to be addressed.

5.4.2 Opportunities

- Personalized Medicine: Advances in genomics and biomarker research pave the way for personalized treatment strategies tailored to individual patient profiles.
- Artificial Intelligence (AI): AI and machine learning algorithms can analyze large datasets to identify patterns and predict disease progression, enhancing early diagnosis and personalized treatment approaches.

5.5 Interdisciplinary and Collaborative Research

5.5.1 Challenges

- Siloed Research Efforts: Research efforts are often fragmented, with limited collaboration between different disciplines and institutions.
- Funding Constraints: Securing adequate funding for comprehensive research projects remains a significant challenge.

5.5.2 Opportunities

- Collaborative Networks: Establishing global research networks and consortia can facilitate data sharing, standardize research protocols, and accelerate the discovery of new therapies.
- Public-Private Partnerships: Collaborations between academic institutions, industry, and government agencies can leverage resources and expertise to address complex research challenges.

6. CONCLUSION

Diabetic neuropathy, caused by long-term high blood sugar, can lead to serious nerve damage and discomfort. By understanding how this condition develops, we see how crucial it is to manage blood sugar levels and reduce oxidative stress. Symptoms can vary widely, from tingling and numbness to pain and weakness, making early and accurate diagnosis essential. While current treatments aim to control blood sugar and relieve symptoms, new therapies are on the horizon that could offer even better results. Future research is key to overcoming current challenges and finding more effective ways to prevent, diagnose, and treat this condition, ultimately improving lives.

II. ACKNOWLEDGMENT

Council of Scientific and Industrial Research Human Resource Development Group (CSIR-HRDG), New Delhi, India provided financial support.

REFERENCES

Adki, K. M., & Kulkarni, Y. A. (2023). Biomarkers in diabetic neuropathy. *Archives of Physiology and Biochemistry*, *129*(2), 460–475. https://doi.org/10.1080/13813455.2020.1837183.

Akbar, S., Subhan, F., Akbar, A., Habib, F., Shahbaz, N., Ahmad, A., Wadood, A., & Salman, S. (2023). Targeting Anti-Inflammatory Pathways to Treat Diabetes-Induced Neuropathy by 6-Hydroxyflavanone. *Nutrients*, *15*(11), 2552. https://doi.org/10.3390/nu15112552.

Akter, S., Choubey, M., Mohib, M. M., Arbee, S., Sagor, M. A. T., & Mohiuddin, M. S. (2023). Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions. *Brain Sciences*, *13*(2), 255. https://doi.org/10.3390/brainsci13020255.

Aloe, L., Rocco, M. L., Omar Balzamino, B., & Micera, A. (2015). Nerve Growth Factor: A Focus on Neuroscience and Therapy. *Current Neuropharmacology*, *13*(3), 294–303. https://doi.org/10.2174/1570159X13666150403231920.

Alonso-Enríquez, L., Gómez-Cuaresma, L., Billot, M., Garcia-Bernal, M. I., Benitez-Lugo, M. L., Casuso-Holgado, M. J., & Luque-Moreno, C. (2023). Effectiveness of Virtual Reality and Feedback to Improve Gait and Balance in Patients with Diabetic Peripheral Neuropathies: Systematic Review and Meta-Analysis. *Healthcare (Basel, Switzerland)*, *11*(23), 3037. https://doi.org/10.3390/healthcare11233037.

Arikawa, E., Ma, R. C. W., Isshiki, K., Luptak, I., He, Z., Yasuda, Y., Maeno, Y., Patti, M. E., Weir, G. C., Harris, R. A., Zammit, V. A., Tian, R., & King, G. L. (2007). Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. *Diabetes*, *56*(5), 1410–1420. https://doi.org/10.2337/db06-0655.

Bhandari, R., Sharma, A., & Kuhad, A. (2022). Novel Nanotechnological Approaches for Targeting Dorsal Root Ganglion (DRG) in Mitigating Diabetic Neuropathic Pain (DNP). *Frontiers in Endocrinology*, *12*. https://doi.org/10.3389/fendo.2021.790747.

Bodman, M. A., Dreyer, M. A., & Varacallo, M. (2024). Diabetic Peripheral Neuropathy. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK442009/.

Bodman, M. A., Dreyer, M. A., & Varacallo, M. (2024). Diabetic Peripheral Neuropathy. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK442009/.

Brognara, L., Mazzotti, A., Di Martino, A., Faldini, C., & Cauli, O. (2021). Wearable Sensor for Assessing Gait and Postural Alterations in Patients with Diabetes: A Scoping Review. *Medicina*, *57*(11), 1145. https://doi.org/10.3390/medicina57111145.

Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. *Nature*, *414*(6865), 813–820. https://doi.org/10.1038/414813a.

Cameron, N. E., & Cotter, M. A. (1993). Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies. *Diabetic Medicine: A Journal of the British Diabetic Association*, *10*(7), 593–605. https://doi.org/10.1111/j.1464-5491.1993.tb00131.x.

Carmichael, J., Fadavi, H., Ishibashi, F., Shore, A. C., & Tavakoli, M. (2021). Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. *Frontiers in Endocrinology*, *12*, 671257. https://doi.org/10.3389/fendo.2021.671257.

Chalk, C., Benstead, T. J., & Moore, F. (2007). Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. *The Cochrane Database of Systematic Reviews*, *2007*(4), CD004572. https://doi.org/10.1002/14651858.CD004572.pub2.

Darmayanti, S., Lesmana, R., Meiliana, A., & Abdulah, R. (2021). Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients. *Current Diabetes Reviews*, *17*(6), e123120189796. https://doi.org/10.2174/1573399817666210101105253.

Dhediya, R., Chadha, M., Bhattacharya, A. D., Godbole, S., & Godbole, S. (2023). Role of Telemedicine in Diabetes Management. *Journal of Diabetes Science and Technology*, *17*(3), 775–781. https://doi.org/10.1177/19322968221081133.

Divisova, S., Vlckova, E., Hnojcikova, M., Skorna, M., Nemec, M., Dubovy, P., Dusek, L., Jarkovsky, J., Belobradkova, J., & Bednarik, J. (2012). Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. *Journal of the Peripheral Nervous System: JPNS*, *17*(3), 341–350. https://doi.org/10.1111/j.1529-8027.2012.00420.x.

Fan, B., Chopp, M., Zhang, Z. G., & Liu, X. S. (2020). Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy. *Frontiers in Neurology*, *11*, 558758. https://doi.org/10.3389/fneur.2020.558758.

Fasoula, N.-A., Xie, Y., Katsouli, N., Reidl, M., Kallmayer, M. A., Eckstein, H.-H., Ntziachristos, V., Hadjileontiadis, L., Avgerinos, D. V., Briasoulis, A., Siasos, G., Hosseini, K., Doulamis, I., Kampaktsis, P. N., & Karlas, A. (2023). Clinical and Translational Imaging and Sensing of Diabetic Microangiopathy: A Narrative Review. *Journal of Cardiovascular Development and Disease*, *10*(9), 383. https://doi.org/10.3390/jcdd10090383.

Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019). Diabetic neuropathy. *Nature Reviews. Disease Primers*, *5*(1), 42. https://doi.org/10.1038/s41572-019-0097-9.

Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017). New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron*, *93*(6), 1296–1313. https://doi.org/10.1016/j.neuron.2017.02.005.

Giurini, J. M., Rosenblum, B. I., & Lyons, T. E. (1998). Management of the Diabetic Foot. In A. Veves (Ed.), *Clinical Management of Diabetic Neuropathy* (pp. 303–318). Humana Press. https://doi.org/10.1007/978-1-4612-1816-6_19.

Huang, S.-K., Lu, C.-W., Lin, T.-Y., & Wang, S.-J. (2022). Neuroprotective Role of the B Vitamins in the Modulation of the Central Glutamatergic Neurotransmission. *CNS & Neurological Disorders Drug Targets*, *21*(4), 292–301. https://doi.org/10.2174/1871527320666210902165739.

Kessler, J. A., Smith, A. G., Cha, B.-S., Choi, S. H., Wymer, J., Shaibani, A., Ajroud-Driss, S., Vinik, A., & Group, V. D.-I. S. (2015). Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. *Annals of Clinical and Translational Neurology*, *2*(5), 465–478. https://doi.org/10.1002/acn3.186.

Khalifa, M., & Albadawy, M. (2024). Artificial intelligence for diabetes: Enhancing prevention, diagnosis, and effective management. *Computer Methods and Programs in Biomedicine Update*, *5*, 100141. https://doi.org/10.1016/j.cmpbup.2024.100141.

Kollmer, J., & Bendszus, M. (2021). Magnetic Resonance Neurography: Improved Diagnosis of Peripheral Neuropathies. *Neurotherapeutics*, *18*(4), 2368–2383. https://doi.org/10.1007/s13311-021-01166-8.

Leinninger, G. M., Backus, C., Sastry, A. M., Yi, Y.-B., Wang, C.-W., & Feldman, E. L. (2006). Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. *Neurobiology of Disease*, *23*(1), 11–22. https://doi.org/10.1016/j.nbd.2006.01.017.

Martin, C. L., Albers, J., Herman, W. H., Cleary, P., Waberski, B., Greene, D. A., Stevens, M. J., Feldman, E. L., & DCCT/EDIC Research Group. (2006). Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. *Diabetes Care*, *29*(2), 340–344. https://doi.org/10.2337/diacare.29.02.06.dc05-1549.

Niimi, N., Yako, H., Takaku, S., Chung, S. K., & Sango, K. (2021). Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems. *International Journal of Molecular Sciences*, *22*(3), 1031. https://doi.org/10.3390/ijms22031031.

Obrosova, I. G., Van Huysen, C., Fathallah, L., Cao, X. C., Greene, D. A., & Stevens, M. J. (2002). An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*, *16*(1), 123–125. https://doi.org/10.1096/fj.01-0603fje.

Onesti, E., Gabriele, M., Cambieri, C., Ceccanti, M., Raccah, R., Di Stefano, G., Biasiotta, A., Truini, A., Zangen, A., & Inghilleri, M. (2013). H-coil repetitive transcranial magnetic stimulation for pain relief in patients with diabetic neuropathy. *European Journal of Pain*, *17*(9), 1347–1356. https://doi.org/10.1002/j.1532-2149.2013.00320.x.

Ong, J., Zarnegar, A., Corradetti, G., Singh, S. R., & Chhablani, J. (2022). Advances in Optical Coherence Tomography Imaging Technology and Techniques for Choroidal and Retinal Disorders. *Journal of Clinical Medicine*, *11*(17), 5139. https://doi.org/10.3390/jcm11175139.

Oyenihi, A. B., Ayeleso, A. O., Mukwevho, E., & Masola, B. (2015). Antioxidant Strategies in the Management of Diabetic Neuropathy. *BioMed Research International*, *2015*, 515042. https://doi.org/10.1155/2015/515042.

Pacher, P., & Szabó, C. (2005). Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. *Antioxidants & Redox Signaling*, *7*(11–12), 1568–1580. https://doi.org/10.1089/ars.2005.7.1568.

Pandey, A., Tripathi, P., Pandey, R., Srivatava, R., & Goswami, S. (2011). Alternative therapies useful in the management of diabetes: A systematic review. *Journal of Pharmacy & Bioallied Sciences*, *3*(4), 504–512. https://doi.org/10.4103/0975-7406.90103.

Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020). Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. *Journal of Diabetes Research*, *2020*, 7489795. https://doi.org/10.1155/2020/7489795.

Parwani, K., & Mandal, P. (2023). Role of advanced glycation end products and insulin resistance in diabetic nephropathy. *Archives of Physiology and Biochemistry*, *129*(1), 95–107. https://doi.org/10.1080/13813455.2020.1797106.

Pop-Busui, R., Ang, L., Boulton, A. J. M., Feldman, E. L., Marcus, R. L., Mizokami-Stout, K., Singleton, J. R., & Ziegler, D. (2022). *Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy*. American Diabetes Association. http://www.ncbi.nlm.nih.gov/books/NBK580224/.

Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2007). Arguing for the motion: Yes, RAGE is a receptor for advanced glycation endproducts. *Molecular Nutrition & Food Research*, *51*(9), 1111–1115. https://doi.org/10.1002/mnfr.200700008.

Rossor, A. M., & Reilly, M. M. (2022). Blood biomarkers of peripheral neuropathy. *Acta Neurologica Scandinavica*, *146*(4), 325–331. https://doi.org/10.1111/ane.13650.

Said, G., Elgrably, F., Lacroix, C., Planté, V., Talamon, C., Adams, D., Tager, M., & Slama, G. (1997). Painful proximal diabetic neuropathy: Inflammatory nerve lesions and spontaneous favorable outcome. *Annals of Neurology*, *41*(6), 762–770. https://doi.org/10.1002/ana.410410612.

Said, G., Lacroix, C., Lozeron, P., Ropert, A., Planté, V., & Adams, D. (2003). Inflammatory vasculopathy in multifocal diabetic neuropathy. *Brain: A Journal of Neurology*, *126*(Pt 2), 376–385. https://doi.org/10.1093/brain/awg029.

Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., Bernardi, L., Valensi, P., & Toronto Diabetic Neuropathy Expert Group. (2010). Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care*, *33*(10), 2285–2293. https://doi.org/10.2337/dc10-1303.

Thornalley, P. J. (2005). The potential role of thiamine (vitamin B1) in diabetic complications. *Current Diabetes Reviews*, *1*(3), 287–298. https://doi.org/10.2174/157339905774574383.

Vargas-Soria, M., García-Alloza, M., & Corraliza-Gómez, M. (2023). Effects of diabetes on microglial physiology: A systematic review of in vitro, preclinical and clinical studies. *Journal of Neuroinflammation*, *20*(1), 57. https://doi.org/10.1186/s12974-023-02740-x.

Vincent, A. M., Perrone, L., Sullivan, K. A., Backus, C., Sastry, A. M., Lastoskie, C., & Feldman, E. L. (2007). Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. *Endocrinology*, *148*(2), 548–558. https://doi.org/10.1210/en.2006-0073.

Wang, E. J., Berninger, L. E., Komargodski, O., & Smith, T. J. (2022). Painful Diabetic Neuropathy - Spinal Cord Stimulation, Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation, and Scrambler Therapy: A Narrative Review. *Pain Physician*, *25*(8), E1163–E1173.

Wang, L., Chopp, M., Szalad, A., Lu, X., Zhang, Y., Wang, X., Cepparulo, P., Lu, M., Li, C., & Zhang, Z. G. (2020). Exosomes Derived From Schwann Cells Ameliorate Peripheral Neuropathy in Type 2 Diabetic Mice. *Diabetes*, *69*(4), 749–759. https://doi.org/10.2337/db19-0432.

Yaghmour, K. A., Abu Sadi, R., Badroun, F., Alali, R., Almubarak, F., Alabbad, Z., Alharthi, N., Samkari, J. A., & Gaddoury, M. A. (n.d.). Complementary and Alternative Medicine Use Among Patients With Diabetes

Mellitus in Saudi Arabia: A Community-Based Cross-Sectional Study. *Cureus*, *15*(9), e45792. https://doi.org/10.7759/cureus.45792.

Zang, Y., Jiang, D., Zhuang, X., & Chen, S. (2023). Changes in the central nervous system in diabetic neuropathy. *Heliyon*, *9*(8), e18368. https://doi.org/10.1016/j.heliyon.2023.e18368.

Zheng, C., Ou, W., Shen, H., Zhou, Z., & Wang, J. (2015). Combined Therapy of Diabetic Peripheral Neuropathy with Breviscapine and Mecobalamin: A Systematic Review and a Meta-Analysis of Chinese Studies. *BioMed Research International*, *2015*, 680756. https://doi.org/10.1155/2015/680756.